Loading...
Header Logo
Keywords
Last Name
Institution

Michelle C Callegan

TitleProf,George L Cross Rsrch
InstitutionUniversity of Oklahoma Health Sciences Center
DepartmentOphthalmology
Phone405/271-3674
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R21EY028066     (CALLEGAN, MICHELLE C)Jan 1, 2019 - Dec 31, 2020
    NIH/NEI
    Targeting Chemokines in Intraocular Infection
    Role: Principal Investigator

    R01EY028810     (CALLEGAN, MICHELLE C)Sep 1, 2018 - Jun 30, 2023
    NIH/NEI
    Pathogenic Mechanisms of Bacillus Endophthalmitis
    Role: Principal Investigator

    R01EY025947     (CALLEGAN, MICHELLE C)Sep 30, 2015 - Aug 31, 2018
    NIH/NEI
    Nanotherapeutics for Ocular Infections
    Role: Principal Investigator

    R01EY024140     (CALLEGAN, MICHELLE C)Jan 1, 2014 - Dec 31, 2017
    NIH/NEI
    Vascular Permeability and Ocular Infections
    Role: Principal Investigator

    R21EY022466     (CALLEGAN, MICHELLE C)Dec 1, 2012 - Nov 30, 2015
    NIH/NEI
    New Models of Endogenous Bacterial Endophthalmitis
    Role: Principal Investigator

    R01EY012985     (CALLEGAN, MICHELLE C)Jun 1, 2000 - Aug 31, 2014
    NIH/NEI
    Mechanisms of Inflammation and Vision Loss in Endophthalmitis
    Role: Principal Investigator

    F32EY006813     (CALLEGAN, MICHELLE C)Aug 10, 1997
    NIH/NEI
    MOLECULAR PATHOGENESIS OF BACILLUS CEREUS ENDOPHTHALMITI
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Montgomery ML, Callegan MC, Fuller KK, Carr DJJ. Ocular Glands Become Infected Secondarily to Infectious Keratitis and Play a Role in Corneal Resistance to Infection. J Virol. 2019 Aug 15; 93(16). PMID: 31167909.
      View in: PubMed
    2. Astley R, Miller FC, Mursalin MH, Coburn PS, Callegan MC. An Eye on Staphylococcus aureus Toxins: Roles in Ocular Damage and Inflammation. Toxins (Basel). 2019 Jun 19; 11(6). PMID: 31248125.
      View in: PubMed
    3. Miller FC, Coburn PS, Huzzatul MM, LaGrow AL, Livingston E, Callegan MC. Targets of immunomodulation in bacterial endophthalmitis. Prog Retin Eye Res. 2019 May 28. PMID: 31150824.
      View in: PubMed
    4. Coburn PS, Miller FC, LaGrow AL, Land C, Mursalin H, Livingston E, Amayem O, Chen Y, Gao W, Zhang L, Callegan MC. Disarming Pore-Forming Toxins with Biomimetic Nanosponges in Intraocular Infections. mSphere. 2019 05 15; 4(3). PMID: 31092603.
      View in: PubMed
    5. Coburn PS, Miller FC, LaGrow AL, Parkunan SM, Blake Randall C, Staats RL, Callegan MC. TLR4 modulates inflammatory gene targets in the retina during Bacillus cereus endophthalmitis. BMC Ophthalmol. 2018 Apr 16; 18(1):96. PMID: 29661181.
      View in: PubMed
    6. LaGrow AL, Coburn PS, Miller FC, Land C, Parkunan SM, Luk BT, Gao W, Zhang L, Callegan MC. A Novel Biomimetic Nanosponge Protects the Retina from the Enterococcus faecalis Cytolysin. mSphere. 2017 Nov-Dec; 2(6). PMID: 29202038.
      View in: PubMed
    7. Callegan MC, Parkunan SM, Randall CB, Coburn PS, Miller FC, LaGrow AL, Astley RA, Land C, Oh SY, Schneewind O. The role of pili in Bacillus cereus intraocular infection. Exp Eye Res. 2017 06; 159:69-76. PMID: 28336259.
      View in: PubMed
    8. Parkunan SM, Randall CB, Astley RA, Furtado GC, Lira SA, Callegan MC. CXCL1, but not IL-6, significantly impacts intraocular inflammation during infection. J Leukoc Biol. 2016 11; 100(5):1125-1134. PMID: 27286792.
      View in: PubMed
    9. Coburn PS, Wiskur BJ, Miller FC, LaGrow AL, Astley RA, Elliott MH, Callegan MC. Bloodstream-To-Eye Infections Are Facilitated by Outer Blood-Retinal Barrier Dysfunction. PLoS One. 2016; 11(5):e0154560. PMID: 27195776.
      View in: PubMed
    10. Astley RA, Coburn PS, Parkunan SM, Callegan MC. Modeling intraocular bacterial infections. Prog Retin Eye Res. 2016 09; 54:30-48. PMID: 27154427.
      View in: PubMed
    11. Venincasa VD, Callegan M, Astley RA, Siatkowski RM. Contact Lens-related Polymicrobial Keratitis from Pantoea agglomerans and Escherichia vulneris. Am J Ophthalmol Case Rep. 2016 Apr; 1:5-7. PMID: 27158679.
      View in: PubMed
    12. Coburn PS, Wiskur BJ, Astley RA, Callegan MC. Blood-Retinal Barrier Compromise and Endogenous Staphylococcus aureus Endophthalmitis. Invest Ophthalmol Vis Sci. 2015 Nov; 56(12):7303-11. PMID: 26559476.
      View in: PubMed
    13. Parkunan SM, Randall CB, Coburn PS, Astley RA, Staats RL, Callegan MC. Unexpected Roles for Toll-Like Receptor 4 and TRIF in Intraocular Infection with Gram-Positive Bacteria. Infect Immun. 2015 Oct; 83(10):3926-36. PMID: 26195555.
      View in: PubMed
    14. Li X, Gu X, Boyce TM, Zheng M, Reagan AM, Qi H, Mandal N, Cohen AW, Callegan MC, Carr DJ, Elliott MH. Caveolin-1 increases proinflammatory chemoattractants and blood-retinal barrier breakdown but decreases leukocyte recruitment in inflammation. Invest Ophthalmol Vis Sci. 2014 Aug 26; 55(10):6224-34. PMID: 25159208.
      View in: PubMed
    15. Parkunan SM, Astley R, Callegan MC. Role of TLR5 and flagella in bacillus intraocular infection. PLoS One. 2014; 9(6):e100543. PMID: 24959742.
      View in: PubMed
    16. Hunt JJ, Astley R, Wheatley N, Wang JT, Callegan MC. TLR4 contributes to the host response to Klebsiella intraocular infection. Curr Eye Res. 2014 Aug; 39(8):790-802. PMID: 24588082.
      View in: PubMed
    17. Pettey JH, Mifflin MD, Kamae K, McEntire MW, Pettey DH, Callegan MC, Brown H, Olson RJ. The impact of short-term topical gatifloxacin and moxifloxacin on bacterial injection after hypodermic needle passage through human conjunctiva. J Ocul Pharmacol Ther. 2013 Jun; 29(5):450-5. PMID: 23425429.
      View in: PubMed
    18. Coburn PS, Wiskur BJ, Christy E, Callegan MC. The diabetic ocular environment facilitates the development of endogenous bacterial endophthalmitis. Invest Ophthalmol Vis Sci. 2012 Nov 01; 53(12):7426-31. PMID: 23036996.
      View in: PubMed
    19. Callegan M, Gregory-Ksander M, Willcox M, Lightman S. Ocular inflammation and infection. Int J Inflam. 2012; 2012:403520. PMID: 23091771.
      View in: PubMed
    20. Novosad BD, Astley RA, Callegan MC. Role of Toll-like receptor (TLR) 2 in experimental Bacillus cereus endophthalmitis. PLoS One. 2011; 6(12):e28619. PMID: 22163046.
      View in: PubMed
    21. Callegan MC, Guess S, Wheatley NR, Woods DC, Griffin G, Wiskur BJ, Leonard R. Efficacy of vitrectomy in improving the outcome of Bacillus cereus endophthalmitis. Retina. 2011 Sep; 31(8):1518-24. PMID: 21606892.
      View in: PubMed
    22. Hunt JJ, Wang JT, Callegan MC. Contribution of mucoviscosity-associated gene A (magA) to virulence in experimental Klebsiella pneumoniae endophthalmitis. Invest Ophthalmol Vis Sci. 2011 Aug 29; 52(9):6860-6. PMID: 21791595.
      View in: PubMed
    23. Olson R, Donnenfeld E, Bucci FA, Price FW, Raizman M, Solomon K, Devgan U, Trattler W, Dell S, Wallace RB, Callegan M, Brown H, McDonnell PJ, Conway T, Schiffman RM, Hollander DA. Methicillin resistance of Staphylococcus species among health care and nonhealth care workers undergoing cataract surgery. Clin Ophthalmol. 2010 Dec 10; 4:1505-14. PMID: 21191448.
      View in: PubMed
    24. Novosad BD, Callegan MC. Severe bacterial endophthalmitis: towards improving clinical outcomes. Expert Rev Ophthalmol. 2010 Oct; 5(5):689-698. PMID: 21572565.
      View in: PubMed
    25. Callegan MC. Checks and balances: the ocular response to infection. Virulence. 2010 Jul-Aug; 1(4):222. PMID: 21178447.
      View in: PubMed
    26. Callegan MC, Novosad BD, Ramadan RT, Wiskur B, Moyer AL. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones. Adv Ther. 2009 Apr; 26(4):447-54. PMID: 19381523.
      View in: PubMed
    27. Moyer AL, Ramadan RT, Novosad BD, Astley R, Callegan MC. Bacillus cereus-induced permeability of the blood-ocular barrier during experimental endophthalmitis. Invest Ophthalmol Vis Sci. 2009 Aug; 50(8):3783-93. PMID: 19264886.
      View in: PubMed
    28. Rajala RV, Wiskur B, Tanito M, Callegan M, Rajala A. Diabetes reduces autophosphorylation of retinal insulin receptor and increases protein-tyrosine phosphatase-1B activity. Invest Ophthalmol Vis Sci. 2009 Mar; 50(3):1033-40. PMID: 19029027.
      View in: PubMed
    29. Wiskur BJ, Hunt JJ, Callegan MC. Hypermucoviscosity as a virulence factor in experimental Klebsiella pneumoniae endophthalmitis. Invest Ophthalmol Vis Sci. 2008 Nov; 49(11):4931-8. PMID: 18586871.
      View in: PubMed
    30. Ramadan RT, Moyer AL, Callegan MC. A role for tumor necrosis factor-alpha in experimental Bacillus cereus endophthalmitis pathogenesis. Invest Ophthalmol Vis Sci. 2008 Oct; 49(10):4482-9. PMID: 18586878.
      View in: PubMed
    31. Wiskur BJ, Robinson ML, Farrand AJ, Novosad BD, Callegan MC. Toward improving therapeutic regimens for Bacillus endophthalmitis. Invest Ophthalmol Vis Sci. 2008 Apr; 49(4):1480-7. PMID: 18385066.
      View in: PubMed
    32. Moyer AL, Ramadan RT, Thurman J, Burroughs A, Callegan MC. Bacillus cereus induces permeability of an in vitro blood-retina barrier. Infect Immun. 2008 Apr; 76(4):1358-67. PMID: 18268029.
      View in: PubMed
    33. Charles E, Callegan MC, Blader IJ. The SAG1 Toxoplasma gondii surface protein is not required for acute ocular toxoplasmosis in mice. Infect Immun. 2007 Apr; 75(4):2079-83. PMID: 17283084.
      View in: PubMed
    34. Callegan MC, Gilmore MS, Gregory M, Ramadan RT, Wiskur BJ, Moyer AL, Hunt JJ, Novosad BD. Bacterial endophthalmitis: therapeutic challenges and host-pathogen interactions. Prog Retin Eye Res. 2007 Mar; 26(2):189-203. PMID: 17236804.
      View in: PubMed
    35. Gregory M, Callegan MC, Gilmore MS. Role of bacterial and host factors in infectious endophthalmitis. Chem Immunol Allergy. 2007; 92:266-275. PMID: 17264502.
      View in: PubMed
    36. Ramadan RT, Ramirez R, Novosad BD, Callegan MC. Acute inflammation and loss of retinal architecture and function during experimental Bacillus endophthalmitis. Curr Eye Res. 2006 Nov; 31(11):955-65. PMID: 17114121.
      View in: PubMed
    37. Callegan MC, Novosad BD, Ramirez R, Ghelardi E, Senesi S. Role of swarming migration in the pathogenesis of bacillus endophthalmitis. Invest Ophthalmol Vis Sci. 2006 Oct; 47(10):4461-7. PMID: 17003440.
      View in: PubMed
    38. Callegan MC, Cochran DC, Kane ST, Ramadan RT, Chodosh J, McLean C, Stroman DW. Virulence factor profiles and antimicrobial susceptibilities of ocular bacillus isolates. Curr Eye Res. 2006 Sep; 31(9):693-702. PMID: 16966141.
      View in: PubMed
    39. Callegan MC, Kane ST, Cochran DC, Novosad B, Gilmore MS, Gominet M, Lereclus D. Bacillus endophthalmitis: roles of bacterial toxins and motility during infection. Invest Ophthalmol Vis Sci. 2005 Sep; 46(9):3233-8. PMID: 16123424.
      View in: PubMed
    40. Callegan MC, Ramirez R, Kane ST, Cochran DC, Jensen H. Antibacterial activity of the fourth-generation fluoroquinolones gatifloxacin and moxifloxacin against ocular pathogens. Adv Ther. 2003 Sep-Oct; 20(5):246-52. PMID: 14964344.
      View in: PubMed
    41. Callegan MC, Kane ST, Cochran DC, Gilmore MS, Gominet M, Lereclus D. Relationship of plcR-regulated factors to Bacillus endophthalmitis virulence. Infect Immun. 2003 Jun; 71(6):3116-24. PMID: 12761089.
      View in: PubMed
    42. Callegan MC, Cochran DC, Kane ST, Gilmore MS, Gominet M, Lereclus D. Contribution of membrane-damaging toxins to Bacillus endophthalmitis pathogenesis. Infect Immun. 2002 Oct; 70(10):5381-9. PMID: 12228262.
      View in: PubMed
    43. Callegan MC, Kane ST, Cochran DC, Gilmore MS. Molecular mechanisms of Bacillus endophthalmitis pathogenesis. DNA Cell Biol. 2002 May-Jun; 21(5-6):367-73. PMID: 12167238.
      View in: PubMed
    44. Ruan X, Chodosh J, Callegan MC, Booth MC, Lee TD, Kumar P, Gilmore MS, Pereira HA. Corneal expression of the inflammatory mediator CAP37. Invest Ophthalmol Vis Sci. 2002 May; 43(5):1414-21. PMID: 11980855.
      View in: PubMed
    45. Callegan MC, Engelbert M, Parke DW, Jett BD, Gilmore MS. Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium-host interactions. Clin Microbiol Rev. 2002 Jan; 15(1):111-24. PMID: 11781270.
      View in: PubMed
    46. Callegan MC, Parke DW, Gilmore MS. Corticosteroid and antibiotic therapy for bacillus endophthalmitis. Arch Ophthalmol. 2001 Sep; 119(9):1391-3. PMID: 11545656.
      View in: PubMed
    47. Booth MC, Pence LM, Mahasreshti P, Callegan MC, Gilmore MS. Clonal associations among Staphylococcus aureus isolates from various sites of infection. Infect Immun. 2001 Jan; 69(1):345-52. PMID: 11119523.
      View in: PubMed
    48. Callegan MC, Booth MC, Gilmore MS. In vitro pharmacodynamics of ofloxacin and ciprofloxacin against common ocular pathogens. Cornea. 2000 Jul; 19(4):539-45. PMID: 10928774.
      View in: PubMed
    49. Callegan MC, Booth MC, Jett BD, Gilmore MS. Pathogenesis of gram-positive bacterial endophthalmitis. Infect Immun. 1999 Jul; 67(7):3348-56. PMID: 10377112.
      View in: PubMed
    50. Callegan MC, Jett BD, Hancock LE, Gilmore MS. Role of hemolysin BL in the pathogenesis of extraintestinal Bacillus cereus infection assessed in an endophthalmitis model. Infect Immun. 1999 Jul; 67(7):3357-66. PMID: 10377113.
      View in: PubMed
    51. Booth MC, Hatter KL, Miller D, Davis J, Kowalski R, Parke DW, Chodosh J, Jett BD, Callegan MC, Penland R, Gilmore MS. Molecular epidemiology of Staphylococcus aureus and Enterococcus faecalis in endophthalmitis. Infect Immun. 1998 Jan; 66(1):356-60. PMID: 9423880.
      View in: PubMed
    52. O'Callaghan RJ, Callegan MC, Moreau JM, Green LC, Foster TJ, Hartford OM, Engel LS, Hill JM. Specific roles of alpha-toxin and beta-toxin during Staphylococcus aureus corneal infection. Infect Immun. 1997 May; 65(5):1571-8. PMID: 9125532.
      View in: PubMed
    53. Booth MC, Cheung AL, Hatter KL, Jett BD, Callegan MC, Gilmore MS. Staphylococcal accessory regulator (sar) in conjunction with agr contributes to Staphylococcus aureus virulence in endophthalmitis. Infect Immun. 1997 Apr; 65(4):1550-6. PMID: 9119503.
      View in: PubMed
    54. O'Callaghan RJ, Engel LS, Hobden JA, Callegan MC, Green LC, Hill JM. Pseudomonas keratitis. The role of an uncharacterized exoprotein, protease IV, in corneal virulence. Invest Ophthalmol Vis Sci. 1996 Mar; 37(4):534-43. PMID: 8595953.
      View in: PubMed
    55. Engel LS, Callegan MC, Hill JM, Folkens AT, Shimomura Y, O'Callaghan RJ. The effectiveness of two ciprofloxacin formulations for experimental Pseudomonas and Staphylococcus keratitis. Jpn J Ophthalmol. 1996; 40(2):212-9. PMID: 8876389.
      View in: PubMed
    56. Johnson MK, Callegan MC, Engel LS, O'Callaghan RJ, Hill JM, Hobden JA, Boulnois GJ, Andrew PW, Mitchell TJ. Growth and virulence of a complement-activation-negative mutant of Streptococcus pneumoniae in the rabbit cornea. Curr Eye Res. 1995 Apr; 14(4):281-4. PMID: 7606914.
      View in: PubMed
    57. Engel LS, Callegan MC, Hobden JA, Reidy JJ, Hill JM, O'Callaghan RJ. Effectiveness of specific antibiotic/steroid combinations for therapy of experimental Pseudomonas aeruginosa keratitis. Curr Eye Res. 1995 Mar; 14(3):229-34. PMID: 7796606.
      View in: PubMed
    58. Callegan MC, Engel LS, Clinch TE, Hill JM, Kaufman HE, O'Callaghan RJ. Efficacy of tobramycin drops applied to collagen shields for experimental staphylococcal keratitis. Curr Eye Res. 1994 Dec; 13(12):875-8. PMID: 7720394.
      View in: PubMed
    59. Callegan MC, O'Callaghan RJ, Hill JM. Pharmacokinetic considerations in the treatment of bacterial keratitis. Clin Pharmacokinet. 1994 Aug; 27(2):129-49. PMID: 7955776.
      View in: PubMed
    60. Callegan MC, Engel LS, Hill JM, O'Callaghan RJ. Corneal virulence of Staphylococcus aureus: roles of alpha-toxin and protein A in pathogenesis. Infect Immun. 1994 Jun; 62(6):2478-82. PMID: 8188373.
      View in: PubMed
    61. Callegan MC, Engel LS, Hill JM, O'Callaghan RJ. Ciprofloxacin versus tobramycin for the treatment of staphylococcal keratitis. Invest Ophthalmol Vis Sci. 1994 Mar; 35(3):1033-7. PMID: 8125714.
      View in: PubMed
    62. Hobden JA, Engel LS, Callegan MC, Hill JM, Gebhardt BM, O'Callaghan RJ. Pseudomonas aeruginosa keratitis in leukopenic rabbits. Curr Eye Res. 1993 May; 12(5):461-7. PMID: 8344069.
      View in: PubMed
    63. Hobden JA, Engel LS, Hill JM, Callegan MC, O'Callaghan RJ. Prednisolone acetate or prednisolone phosphate concurrently administered with ciprofloxacin for the therapy of experimental Pseudomonas aeruginosa keratitis. Curr Eye Res. 1993 May; 12(5):469-73. PMID: 8344070.
      View in: PubMed
    64. Callegan MC, Hill JM, Insler MS, Hobden JA, O'Callaghan RJ. Methicillin-resistant Staphylococcus aureus keratitis in the rabbit: therapy with ciprofloxacin, vancomycin and cefazolin. Curr Eye Res. 1992 Nov; 11(11):1111-9. PMID: 1483341.
      View in: PubMed
    65. Callegan MC, Hobden JA, Hill JM, Insler MS, O'Callaghan RJ. Topical antibiotic therapy for the treatment of experimental Staphylococcus aureus keratitis. Invest Ophthalmol Vis Sci. 1992 Oct; 33(11):3017-23. PMID: 1399405.
      View in: PubMed
    Callegan's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description